10X Genomics v. Parse Biosciences — Federal Circuit Affirms Obviousness of Single-Cell Analysis Patents

Background

10X Genomics owned three patents covering methods for analyzing nucleic acids from individual cells. Parse Biosciences challenged the patents through inter partes review (IPR), a Patent Trial and Appeal Board process for testing patent validity against earlier patents and publications.

The challenged methods use tag sequences—often called barcodes—to associate genetic material with its source cell and to manage uncertainty introduced when nucleic acids are copied. The PTAB concluded that all challenged claims were obvious over combinations built principally from two prior-art references, Linnarsson and McCloskey. It found that a skilled scientist would have combined their teachings to reduce amplification bias and could attach a second tag by ligation, a conventional laboratory technique.

10X appealed the three final written decisions together. It challenged the Board’s motivation-to-combine findings, its treatment of claim language requiring correlation to a cell, and its conclusion that ligation was an obvious design choice.

The Court’s Holding

In a nonprecedential opinion by Judge Cunningham, the Federal Circuit affirmed every challenged determination. For one patent, the court held that 10X had not presented to the Board the particular motivation-to-combine theory it advanced on appeal. The Board addressed the arguments actually made during the IPR, and 10X did not establish harmful error.

For the other patents, substantial evidence supported the finding that combining the references would reduce amplification bias—the problem that repeated copying can make it difficult to identify the source of genetic material. Expert testimony and the references supported using an added tag to preserve source information. Because that rationale independently justified the combination, the court did not need to resolve every challenge to the Board’s alternative design-choice reasoning.

The court also rejected 10X’s claim-language argument. Although McCloskey’s batch stamp tracked batches rather than individual cells, Linnarsson supplied the cell-specific tag. The proposed combination divided Linnarsson’s native tag into portions, and the record supported the Board’s finding that the resulting method met the correlation limitation.

Finally, the evidence supported adding the second tag through ligation. The patents themselves described ligation as conventional, experts explained that there were only two practical ways to add the tag, and adding it later gave scientists flexibility. Choosing between a small number of known alternatives was an obvious use of prior-art elements.

Key Takeaways

• Patent owners must preserve specific objections before the PTAB; a reframed motivation-to-combine argument may be unavailable on appeal.
• A single supported motivation can sustain an obviousness ruling even when the Board offered additional rationales.
• Conventional laboratory techniques and a limited menu of known design choices can strongly support obviousness.

Why It Matters

The ruling underscores how difficult it is to overturn PTAB factual findings when the record includes detailed expert support and the patent itself labels a technique conventional. Biotechnology patents that combine known tagging and processing steps need a clear, non-obvious technical advance—not merely flexibility obtained by selecting among familiar methods.

For IPR litigants, the decision is also a procedural warning: appellate arguments must match the disputes presented to the Board. A potentially stronger theory developed after the final written decision may come too late.